194 related articles for article (PubMed ID: 8835487)
1. [Early detection and preoperative diagnosis of ovarian carcinoma].
Kainz C
Wien Med Wochenschr; 1996; 146(1-2):2-7. PubMed ID: 8835487
[TBL] [Abstract][Full Text] [Related]
2. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
3. Screening for ovarian cancer.
Jacobs I; Oram D
Biomed Pharmacother; 1988; 42(9):589-96. PubMed ID: 3071382
[TBL] [Abstract][Full Text] [Related]
4. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
[TBL] [Abstract][Full Text] [Related]
6. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
de Bruijn HW; van der Zee AG; Aalders JG
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer screening: a look at the evidence.
Fields MM; Chevlen E
Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
[TBL] [Abstract][Full Text] [Related]
8. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Cane P; Azen C; Lopez E; Platt LD; Karlan BY
Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
[TBL] [Abstract][Full Text] [Related]
9. Screening and detection of ovarian cancer.
Breedlove G; Busenhart C
J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
[TBL] [Abstract][Full Text] [Related]
10. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
11. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
[TBL] [Abstract][Full Text] [Related]
12. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center.
Muto MG; Cramer DW; Brown DL; Welch WR; Harlow BL; Xu H; Brucks JP; Tsao SW; Berkowitz RS
Gynecol Oncol; 1993 Oct; 51(1):12-20. PubMed ID: 8244166
[TBL] [Abstract][Full Text] [Related]
13. [Screening for ovarian cancers: critical analysis].
Pennehouat G; Gugliemina JN; Naouri M; Créquat J; Bouret JM; Thébault Y; Madelenat P
Contracept Fertil Sex; 1993 Mar; 21(3):223-30. PubMed ID: 7951617
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
15. [Screening for ovarian cancer].
Bjørge T; Dørum A; Tropé CG
Tidsskr Nor Laegeforen; 2000 May; 120(12):1444-8. PubMed ID: 10851943
[TBL] [Abstract][Full Text] [Related]
16. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
17. ACR appropriateness criteria© ovarian cancer screening.
Brown DL; Andreotti RF; Lee SI; Dejesus Allison SO; Bennett GL; Dubinsky T; Glanc P; Horrow MM; Lev-Toaff AS; Horowitz NS; Podrasky AE; Scoutt LM; Zelop CM
Ultrasound Q; 2010 Dec; 26(4):219-23. PubMed ID: 21084936
[TBL] [Abstract][Full Text] [Related]
18. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
19. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
20. [Tumor markers in epithelial ovarian cancer].
Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
